#USA #Piramal Pharma #Riverview #Payload-Linker

Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite in Riverview

Piramal Pharma Solutions, a prominent global Contract Development and Manufacturing Organization (CDMO), has officially launched an advanced payload-linker suite at its Riverview, Michigan facility. This new unit is part of a significant $90 million investment plan aimed at expanding production capabilities in the United States. The Riverview site is recognized for its comprehensive services related to active pharmaceutical ingredients (API) and highly potent active pharmaceutical ingredients (HPAPI), and now it will enhance its offerings with specialized solutions for payload-linkers.

The cutting-edge payload-linker suite is set to boost the company's ability to support the global development and manufacturing of payload-linkers, which are crucial for complex therapies, including antibody-drug conjugates (ADCs) and other bioconjugates. This launch highlights Piramal's commitment to innovation and agility in the biopharmaceutical sector, enabling partners to bring life-changing therapies to market more efficiently.

Peter DeYoung, CEO of Piramal Global Pharma, stated, "The introduction of our new payload-linker suite at Riverview signifies a major milestone for PPS and our partners. This facility provides world-class expertise and top-notch technology in the realm of payload-linkers at a commercial scale right here in Michigan. This investment underscores our deep commitment to innovation and manufacturing in the U.S., ensuring our partners benefit from unmatched efficiency and supply chain security."

With over 60 years of experience in the field, the Riverview facility has established itself as a leader in the development and production of APIs. It offers a full range of capabilities catering to both APIs and HPAPIs, leveraging its extensive knowledge to facilitate the rapid and integrated ADC development process known as ADCelerate™. The addition of this new payload-linker suite will further enhance PPS's ability to reduce lead times for partners and adapt to changing market needs.

Equipped with state-of-the-art containment, automation, and analytical technologies, the payload-linker suite enables integrated scaling of linker programs, complementing the ADCelerate™ platform. This advancement positions PPS to meet the increasing demand for ADCs and other bioconjugated therapies effectively.

This strategic expansion not only boosts the capabilities of the Riverview facility but also reinforces its role as a preferred partner for innovative companies seeking patient-centered drug development and manufacturing solutions based in the U.S.

Piramal Pharma Solutions offers end-to-end development and manufacturing services throughout the lifecycle of drugs. The organization operates a globally integrated network of facilities across North America, Europe, and Asia, allowing it to provide a comprehensive range of services, from drug discovery and process development to commercial supply of APIs and finished pharmaceutical dosage forms. Furthermore, PPS specializes in the development and manufacturing of highly potent active pharmaceutical ingredients and antibody-drug conjugates, as well as sterile filling and finishing, peptide products, and related services.

In conclusion, with this new state-of-the-art payload-linker suite, Piramal Pharma Solutions is well-positioned to address the rising needs of the biotechnology industry for innovative and efficient drug development solutions. The advancements made at the Riverview and Lexington facilities illustrate the essential role of PPS in the global pharmaceutical landscape and its unwavering focus on delivering unique drug solutions that improve patient outcomes.